Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Cutaneous Lupus Erythematosus pipeline constitutes 8+ key companies continuously working towards developing 10+ Cutaneous Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Cutaneous Lupus Erythematosus Overview
Cutaneous Lupus Erythematosus (CLE), is an autoimmune disease that can present as an isolated skin disease or as a manifestation within the spectrum of systemic lupus erythematosus. Cutaneous LE can occur as a manifestation of systemiclupus erythematosus (SLE) or independent of SLE.
“Cutaneous Lupus Erythematosus Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cutaneous Lupus Erythematosus Market.
The Cutaneous Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cutaneous Lupus Erythematosus Pipeline Report:
- Companies across the globe are diligently working toward developing novel Cutaneous Lupus Erythematosus treatment therapies with a considerable amount of success over the years. Cutaneous Lupus Erythematosus Key players such as – Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, and others, are developing therapies for the Cutaneous Lupus Erythematosus treatment
- Cutaneous Lupus Erythematosus Emerging therapies such as – HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others are expected to have a significant impact on the Cutaneous Lupus Erythematosus market in the coming years.
- In January 2023, Daxdilimab, a development-stage drug that may be a first-in-class fully human monoclonal antibody targeting anti-ILT7 depletes specific dendritic cells to treat people with moderate-to-severe primary discoid lupus erythematosus, was announced to have enrolled the first patient in a Phase 2 randomised, placebo-controlled trial by Horizon Therapeutics plc (Nasdaq: HZNP) (DLE)
- In April 2021, Sanofi initiated a randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute ordiscoid/chronic cutaneous lupus erythematosus
Route of Administration
Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Cutaneous Lupus Erythematosus Pipeline Therapeutics Assessment
- Cutaneous Lupus Erythematosus Assessment by Product Type
- Cutaneous Lupus Erythematosus By Stage and Product Type
- Cutaneous Lupus Erythematosus Assessment by Route of Administration
- Cutaneous Lupus Erythematosus By Stage and Route of Administration
- Cutaneous Lupus Erythematosus Assessment by Molecule Type
- Cutaneous Lupus Erythematosus by Stage and Molecule Type
DelveInsight’s Cutaneous Lupus Erythematosus Report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Cutaneous Lupus Erythematosus Therapeutics Market include:
Sanofi, Bristol Myers Squibb, Merck, and others
Emerging Cutaneous Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:
- HT-005: Hoth Therapeutics
- CBS004: Centessa Pharmaceuticals
- BMS-986256: Bristol-Myers Squibb
- M5049: Merck
- BMS-986165 (deucravacitinib): Bristol-Myers Squibb
- BIIB059: Biogen
- SAR443122: Sanofi
Get a Free Sample PDF Report to know more about Cutaneous Lupus Erythematosus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-cle-pipeline-insight
Cutaneous Lupus Erythematosus Pipeline Analysis:
The Cutaneous Lupus Erythematosus pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous Lupus Erythematosus with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous Lupus Erythematosus Treatment.
- Cutaneous Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Cutaneous Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous Lupus Erythematosus market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Cutaneous Lupus Erythematosus product details are provided in the report. Download the Cutaneous Lupus Erythematosus pipeline report to learn more about the emerging Cutaneous Lupus Erythematosus therapies
Scope of Cutaneous Lupus Erythematosus Pipeline Drug Insight
- Coverage: Global
- Key Cutaneous Lupus Erythematosus Companies: Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, and others
- Key Cutaneous Lupus Erythematosus Therapies: HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others
- Cutaneous Lupus Erythematosus Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and Cutaneous Lupus Erythematosus emerging therapies
- Cutaneous Lupus Erythematosus Market Dynamics: Cutaneous Lupus Erythematosus market drivers and Cutaneous Lupus Erythematosus market barriers
Request for Sample PDF Report for Cutaneous Lupus Erythematosus Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Cutaneous Lupus Erythematosus Report Introduction |
|
2 |
Cutaneous Lupus Erythematosus Executive Summary |
|
3 |
Cutaneous Lupus Erythematosus Overview |
|
4 |
Cutaneous Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Cutaneous Lupus Erythematosus Pipeline Therapeutics |
|
6 |
Cutaneous Lupus Erythematosus Late Stage Products (Phase II/III) |
|
7 |
Cutaneous Lupus Erythematosus Mid Stage Products (Phase II) |
|
8 |
Cutaneous Lupus Erythematosus Early Stage Products (Phase I) |
|
9 |
Cutaneous Lupus Erythematosus Preclinical Stage Products |
|
10 |
Cutaneous Lupus Erythematosus Therapeutics Assessment |
|
11 |
Cutaneous Lupus Erythematosus Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Cutaneous Lupus Erythematosus Key Companies |
|
14 |
Cutaneous Lupus Erythematosus Key Products |
|
15 |
Cutaneous Lupus Erythematosus Unmet Needs |
|
16 |
Cutaneous Lupus Erythematosus Market Drivers and Barriers |
|
17 |
Cutaneous Lupus Erythematosus Future Perspectives and Conclusion |
|
18 |
Cutaneous Lupus Erythematosus Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Cutaneous Lupus Erythematosus drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting